ObsEva Announces Additional Efficacy Results for Linzagolix
-Reductions in dysmenorrhea (DYS) and non-menstrual pelvic pain (NMPP), the co-primary efficacy endpoints, compared to placebo were observed for both doses...
Source: globenewswire.com
Page 13 - Nasdaq Obsv News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq Obsv. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Obsv Today - Breaking & Trending Today
ObsEva (NASDAQ:OBSV) Lowered to "Sell" at StockNews.com
StockNews.com lowered shares of ObsEva (NASDAQ:OBSV – Get Rating) from a hold rating to a sell rating in a research note released on Monday morning. A number of other research analysts also recently weighed in on the stock. Zacks Investment Research upgraded shares of ObsEva from a sell rating to a hold rating in a […]
Source: etfdailynews.com
ObsEva Announces Positive Topline Results for Linzagolix
-Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain...
Source: globenewswire.com
ObsEva Announces Positive Topline Results for Linzagolix
-Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain...
Source: globenewswire.com
ObsEva Appoints Will Brown as Chief Financial Officer
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 13, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a...
Source: globenewswire.com